Brought to you by 
Aastrom buys Sanofi's cell therapy and regenerative medicine business for $6.5mm
21 Aug 2020
Executive Summary
Sanofi sold its Cell Therapy and Regenerative Medicine (CTRM) business to Aastrom Biosciences Inc. (multicellular therapies for cardiovascular diseases) for a total of $6.5mm ($4mm in cash and the rest in a promissory note).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Divestiture
- Full Acquisition
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aastrom buys Sanofi's cell therapy and regenerative medicine business for $6.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice